Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2005-05-10
2005-05-10
Richter, Johann (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S851000, C514S958000
Reexamination Certificate
active
06890907
ABSTRACT:
A patient suffering from an endobronchial infection is treated by administering to the patient for inhalation a dose of less than about 4.0 ml of a nebulized aerosol formulation comprising from about 60 to about 200 mg/ml of an aminoglycoside antibiotic, such as tobramycin, in a physiologically acceptable carrier in a time period of less than about 10 minutes. Unit dose devices for storage and delivery of the aminoglycoside antibiotic formulations are also provided.
REFERENCES:
patent: 5508269 (1996-04-01), Smith et al.
patent: 6083922 (2000-07-01), Montgomery
patent: 6387886 (2002-05-01), Montgomery et al.
patent: WO 9843650 (1998-10-01), None
patent: WO 0035461 (2000-06-01), None
“TOBI® Tobramycin Solution for Inhalation,”Prescribing Information, Chiron Corporation, Emeryville, Calif., Apr. 2000, 4 pp.
Standaert, T.A., et al., “The Choice of Compressor Effects the Aerosol Parameters and the Delivery of Tobramycin From a Single Model Nebulizer,”J. Aerosol Medicine 13(2):147-153, 2000.
“PathoGenesis-Inks Deal With AeroGen,”Puget Sound Business Journal, ©2000 American City Business Journals Inc., <http://seattle.bizjournals.com/seattle/stories/2000/02/daily15.html> [retrieved Apr. 15, 2004].
Ho, S.L., and A.L. Coates, “Effects of Dead Volume on the Efficiency and the Cost to Deliver Medications in Cystic Fibrosis With Four Disposable Nebulizers,”Can. Respir. J. 6(3):253-260, 1999.
Kendrick, A.H., et al., “Selecting and Using Nebuliser Equipment,”Thorax 52(Suppl 2):S92-S101, 1997.
Coates, A.L., et al., “The Choice of Jet Nebulizer, Nebulizing Flow, and Addition of Albuterol Affects the Output of Tobramycin Aerosols,”Chest 111(5):1206-1212, 1997.
Weber, A., et al., “Effect of Nebulizer Type and Antibiotic Concentration on Device Performance,”Pediatric Pulmonology 23:249-260, 1997.
Touw, D.J., et al., “Pharmacokinetics of Aerosolized Tobramycin in Adult Patients With Cystic Fibrosis,”Antimicrobial Agents and Chemotherapy 41:184-187, 1997.
Faurisson, F., et al., “Étude Comparative sur les Performances et l'Ergonomie de Nébuliseurs dans la Mucoviscidose,”Rev. Mal. Resp. 13:155-162, 1996.
Nikolaizik, W.H., et al., “Bronchial Constriction After Nebulized Tobramycin Preparations and Saline in Patients With Cystic Fibrosis,”Eur. J. Pediatrics 155:608-611, 1996.
Weber, A., et al., “Tobramycin Serum Concentrations After Aerosol and Oral Administration in Cystic Fibrosis,”Am. J. Therapeutics 2:81-87, 1995.
Weber, A., et al., “Nebulizer Delivery of Tobramycin to the Lower Respiratory Tract,”Pediatric Pulmonology 17, 331-339, 1994.
Cooney, G.F., et al., “Absolute Bioavailability and Absorption Characteristics of Aerosolized Tobramycin in Adults With Cystic Fibrosis,”Clin. Pharmacol. 34:255-259, 1994.
Littlewood, J.M., et al., “Aerosol Antibiotic Treatment in Cystic Fibrosis,”Archives of Disease in Childhood 68:788-792, 1993.
Le Conte, P., et al., “Lung Distribution and Pharmacokinetics of Aerosolized Tobramycin,”Am. Rev. Respir. Dis. 147:1279-1282, 1993.
Ramsey, B.W., et al., “Efficacy of Aerosolized Tobramycin in Patients With Cystic Fibrosis,”New England J. Med. 328:1740-1746, 1993.
Makhoul, I.R., et al., “Antibiotic Treatment of ExperimentalPseudomonas aeruginosaPneumonia in Guinea Pigs: Comparison of Aerosol and Systemic Administration,”J. Infectious Diseases 168:1296-1299, 1993.
Valcke, Y.J., and R.A. Pauwels, “Pharmocokinetic Evaluation of Tobramycin in the Alveolar Lining Fluid of the Rat After Endotracheal Administration,”Am. Rev. Respir. Dis. 144:1199-1201, 1991.
Smith, A.L., et al., “Safety of Aerosol Tobramycin Administration for 3 Months to Patients With Cystic Fibrosis,”Pediatric Pulmonology 7:265-271, 1989.
MacLusky, I.B., et al., “Long-Term Effects of Inhaled Tobramycin in Patients With Cystic Fibrosis Colonized WithPseudomonas aeruginosa,” Pediatric Pulmonology 7:42-48, 1989.
Steinkamp, G., et al., “Long-Term Tobramycin Aerosol Therapy in Cystic Fibrosis,”Pediatric Pulmonology 6:91-98, 1989.
Durrani, F.K., et al., “Evaluation of a New, Shorter Method of Administration of Adrenergic Aerosols in the Treatment of Asthma,”Annals of Allergy 61:147-150, 1988.
Geller, D.E., et al., “Efficiency of pulmonary administration of tobramycin solution for inhalation in cystic fibrosis using an improved drug delivery system,”Chest 123:28-36, 2003.
Challoner Peter Bruce
Schaeffler Barbara Ann
Speirs Robert John
Blackburn Robert
Chiron Corporation
Collier Steven W.
Sackey Ebenezer
Shelton Dennis K.
LandOfFree
Methods and unit dose formulations for the inhalation... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and unit dose formulations for the inhalation..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and unit dose formulations for the inhalation... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3388978